Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

TAONas-LUAD

Financiado

Therapeutic Antisense Oligonucleotides Targeting NUMB Alternative Splicing in Lu...

Therapeutic Antisense Oligonucleotides Targeting NUMB Alternative Splicing in Lung Adenocarcinoma Lung cancer is the leading cause of cancer-related deaths, with 1.8 million deaths expected globally in 2021. Lung adenocarcinomas (LUAD) represent 1/3 of all lung cancer cases. Despite notable advances, current treatments remain... ver más

31/12/2025

FUNDACIO PRIVADA C...

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

FUNDACIO PRIVADA CENTRE DE REGULACIO GENOMICA Otras actividades deportivas asociacion

TRL 4-5 | 50K€

Ver 4 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-04-13

HORIZON-EIC-2021-TRANSITIONOPEN-01: EIC Transition Open 2021 Scope:The EIC Transition Open aims at funding innovation activities that go beyond the experimental...

I+D

Cerrada hace 3 años

0% 100% 100%

4 Participantes

FUNDACIO PRIVADA CENTRE DE R...

1.70M€ | Lider

INSERM

435.00K€ | Participante

SINTEF

483.43K€ | Participante

INVENIAM GROUP

280.44K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PDC2021-121832-I00 EFECTOS TERAPEUTICOS DE LA MODULACION DEL SPLICING ALTERNATI... 150K€ Cerrado

PID2019-109577RA-I00 ONECUT2: NUEVA DIANA TERAPEUTICA EN CANCER DE PULMON DE CELU... 109K€ Cerrado

VALSL Valorisation of splice switching oligonucleotides for lung c... 150K€ Cerrado

SAF2017-85352-R REPROGRAMACION METABOLICA Y EPIGENETICA MEDIADA POR NNMT DUR... 109K€ Cerrado

PLEC2021-007959 USO DE LA INHIBICIÓN DE MYC PARA SUPERAR LA RESISTENCIA A LA... 378K€ Cerrado

PID2021-124564OB-I00 INMUNOINTERACTOMA DE RECEPTORES LINFOCITICOS Y PEQUEÑOS PEPT... 121K€ Cerrado

Duración del proyecto: 44 meses Fecha Inicio: 2022-04-13
Fecha Fin: 2025-12-31

Líder del proyecto

FUNDACIO PRIVADA CENTRE DE REGULACIO GENOMICA Otras actividades deportivas asociacion

TRL 4-5 | 50K€

Presupuesto del proyecto 3M€

Descripción del proyecto Lung cancer is the leading cause of cancer-related deaths, with 1.8 million deaths expected globally in 2021. Lung adenocarcinomas (LUAD) represent 1/3 of all lung cancer cases. Despite notable advances, current treatments remain ineffective, resulting in <25% survival beyond 5 years. Due to the high heterogeneity of molecular abnormalities driving lung cancers, targeted therapies are applicable to only a small subset of patients. There is therefore an urgent unmet need for developing novel therapeutic approaches generally applicable to LUAD patients. Alternative pre-mRNA splicing (AS) allows the synthesis of different protein variants from a single gene by differential selection of exonic sequences. Increased inclusion of exon 9 of the gene NUMB encodes a protein isoform that promotes cancer cell proliferation. This occurs in the vast majority of LUAD tumours, correlating with worse disease prognosis. Supported by the ERC PoC VALSL, we developed an innovative therapeutic approach based on the use of Antisense Oligonucleotides (AONs) that regulate NUMB AS. Our proprietary AONs correct NUMB pathological splicing, inhibit cancer cell proliferation and reduce tumour growth in four different mouse models of LUAD, including 2 Patient-Derived Xenograft models. With support from the EIC Transition, we will bring this technology to a stage where it is ready to be validated in clinical trials. We will optimise our lead AONs by improving their chemistry, formulation and administration and will carry out regulatory pre-clinical studies. These will pave the way to the first application of AON-based splicing modulation in clinical oncology. To commercialise this technology, we also aim to develop the business plan for a spin-off company, AON Therapeutics. In the long term, our project has the potential to generate compounds, presentations and delivery methods that can be applicable to other target AS events and/or cancer types, as well as to other AS-related diseases.

Conecta tu I+D

Entra hoy

¿Olvidó su contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores